2020
Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer.
Sella T, Gelber S, Poorvu P, Kim H, Guzman Arocho Y, Collins L, Ruddy K, Tamimi R, Peppercorn J, Schapira L, Borges V, Come S, Warner E, Snow C, Jakubowski D, Russell C, Winer E, Rosenberg S, Partridge A. Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer. Journal Of Clinical Oncology 2020, 38: 514-514. DOI: 10.1200/jco.2020.38.15_suppl.514.Peer-Reviewed Original ResearchPathologic complete responseBreast Recurrence ScoreNeoadjuvant chemotherapyBreast cancerRecurrence scoreBreast Cancer StudyYoung womenHER2- BCEstrogen receptor-positive early breast cancerHER-2 negative breast cancerReceptor-positive early breast cancerYoung Women's Breast Cancer StudyNeoadjuvant endocrine therapyResidual invasive tumorEarly breast cancerPost-menopausal womenNegative breast cancerHigh gradeLogistic regression modelingAdjuvant chemotherapyDuctal histologyPgR negativityEndocrine therapyNeoadjuvant therapyProspective cohortALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
Ma C, Suman V, Leitch A, Sanati S, Vij K, Unzeitig G, Hoog J, Watson M, Hahn O, Guenther J, Caudle A, Dockter T, Korde L, Weiss A, Hunt K, Hudis C, Winer E, Partridge A, Carey L, Ellis M. ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. Journal Of Clinical Oncology 2020, 38: 504-504. DOI: 10.1200/jco.2020.38.15_suppl.504.Peer-Reviewed Original ResearchHER2- BCEstrogen receptor-positive HER2-negative breast cancerClinical stage II/IIIBreast conservation surgery (BCS) ratesHER2-negative breast cancerRecurrence-free survival ratesStage II/IIIClinical stage IIPathologic complete responseWk 4Chi-square testAdjuvant chemotherapyCN1-3Neoadjuvant phasePrimary endpointAlone armPostmenopausal womenComplete responseLoading dosePM patientsBCS ratesSurgery ratesPO dailyBreast cancerLower risk
2009
Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.
Dang C, Lin N, Moy B, Come S, Lake D, Theodoulou M, Troso-Sandoval T, Dickler M, Gorsky M, D'Andrea G, Modi S, Seidman A, Drullinsky P, Partridge A, Schapira L, Wulf G, Gilewski T, Atieh D, Mayer E, Isakoff S, Sugarman S, Fornier M, Traina T, Bromberg J, Currie V, Robson M, Burstein H, Overmoyer B, Ryan P, Kuter I, Younger J, Schumer S, Tung N, Zarwan C, Schnipper L, Chen C, Winer E, Norton L, Hudis C. Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results. Cancer Research 2009, 69: 2108. DOI: 10.1158/0008-5472.sabcs-2108.Peer-Reviewed Original ResearchDd ACHER2- BCLVEF declineDose reductionHER2/neu-positive breast cancerCongestive heart failure ratesNeu-positive breast cancerAsymptomatic LVEF declineCardiac event rateDose-dense doxorubicinHeart failure ratesDose delaysExcessive diarrheaWeekly paclitaxelMedian ageCardiac safetyMonth 2Breast cancerEvent ratesCancer ResDiarrheaPilot studyLVEFLapatinibBaseline